The list of illnesses that seem to benefit from treatment with GLP-1 agonists seems to get ever longer, and a study has ...

Reimbursement authority NICE has turned down routine NHS use of Roche's Itovebi for a specific form of breast cancer, a ...

August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...

Fragmented data does more than slow trials down. In some cases, it can limit eligible patients from participating in a trial ...